Chattem Explained

Chattem, Inc.
Type:Subsidiary
Foundation:Tennessee (January 30, 1879, as the Chattanooga Medicine Company)
Location City:Chattanooga, Tennessee
Key People:Zan Guerry, Chairman, Shaquille O'Neal, brand spokesman, IcyHot and Gold Bond
Industry:healthcare
Over-the-counter-drug manufacturing
Products:Allegra, Gold Bond, ACT Mouthwash, Cortizone-10, Flexall, IcyHot, Sun-In, Ultra Swim, Pamprin, Premsyn, Kaopectate, Dexatrim, Aspercreme, Selsun Blue, Nasacort, Unisom, Capzasin, Benzodent, Herpecin-L, Garlique, and New Phase
Revenue:$1 Billion (USD) (2013)
Parent:Sanofi
Num Employees:536[1]
Homepage:Chattem.com

Chattem, Inc. is an American, Chattanooga, Tennessee-based, producer and marketer of over-the-counter healthcare products, toiletries, dietary supplements, topical analgesics, and medicated skin care products. Originally named the Chattanooga Medicine Company, the company’s brand portfolio holds twenty-two brands including Allegra, Gold Bond, Flexall, IcyHot, Rolaids, Sun-In, Pamprin, Dexatrim, Aspercreme, and Selsun Blue. The company produces two-thirds of its products at its Chattanooga production facilities with the remaining produced by third-party producers. The company is a subsidiary of the French multinational pharmaceutical company Sanofi.

The company’s brands are sold nationally through mass merchandiser, drug and food retailers. In 2005, 70% of the firm's sales were made through its top ten customers, which include Wal-Mart, Walgreens, and Kroger. Sales to Wal-Mart constituted 36% of Chattem’s total sales in 2005. Chattem supports these sales with a forty-five-person sales force and broadcast media advertising. Chattem has market penetration in the United States, Europe, Canada, Latin America, and the Caribbean.

History

Recent events

In October 2006, Chattem announced it would acquire five brands for $410 million as a result of the merger between Johnson & Johnson and the consumer healthcare business of Pfizer. These brands are:

Pending the US government’s approval of the merger of Johnson & Johnson and Pfizer Consumer Healthcare, Chattem will acquire five brands divested from the firms. Chattem has announced it expects to take possession of the brands around January 2007. These mature brands will provide $150 million in additional revenue to Chattem per year.

On December 21, 2009, Paris-based (France) Sanofi, the world's fourth largest drugmaker, said it was acquiring Chattem in a $1.9 billion cash deal. Sanofi said the acquisition would be completed by the first quarter of 2010.[6]

Current brands

Chattem manufactures many over-the-counter healthcare products. They are marketed in three categories: pain relief, skin & hair care, and health & wellness.

Pain relief

Skin & hair care

Health & wellness

External links

Notes and References

  1. Web site: Archived copy . 2011-11-12 . https://web.archive.org/web/20120508051606/http://en.sanofi.com/Images/16370_Chattem_Presentation_2010-03_EN.pdf . 2012-05-08 . dead .
  2. Web site: Chattem . 2011-11-12 . dead . https://web.archive.org/web/20111102232131/http://chattem.com/about08.asp . 2011-11-02 .
  3. News: Johnson & Johnson sells its troubled Rolaids brand to Sanofi. Friedman. Alexi. 8 January 2013. The Star-Ledger. 9 September 2013.
  4. News: Rolaids next on Chattanooga-based Chattem's plate. Pare. Mike. 9 January 2013. Chattanooga Times Free Press. 9 September 2013.
  5. News: NVE Pharmaceuticals Announces the Acquisition of Dexatrim to the Stacker2 Family. March 11, 2014. PRWeb. September 26, 2018.
  6. http://economictimes.indiatimes.com/news/international-business/Sanofi-to-acquire-Chattem-expand-presence-in-US/articleshow/5363994.cms "Sanofi to Acquire Chattem", The Economic Times (December 22, 2009)